Peptide Comparison
VesilutevsProstamax
Tissue-specific dipeptide bioregulator (Glu-Asp) that epigenetically normalizes urogenital function through chromatin remodeling, anti-inflammatory cytokine regulation, and smooth muscle tone restoration in the bladder and prostate
Prostate-specific tetrapeptide bioregulator (Lys-Glu-Asp-Pro) that normalizes prostatic epithelial differentiation through chromatin remodeling at prostate gene promoters, restores the proliferation-apoptosis balance disrupted in benign prostatic hyperplasia, and reduces inflammatory cytokine signaling in aging prostate tissue
At a Glance
Quick
comparison
Dose Range
Vesilute
20–40 mg
Prostamax
5–10 mg
Frequency
Vesilute
Once daily
Prostamax
Once daily
Administration
Vesilute
Oral (capsule/tablet)
Prostamax
Sublingual (enteric-coated capsules)
Cycle Length
Vesilute
12+ weeks
Prostamax
12+ weeks
Onset Speed
Vesilute
Gradual (3-4 weeks)
Prostamax
Gradual (3-4 weeks)
Evidence Level
Vesilute
Moderate human trials (Phase 1-2)
Prostamax
Limited human trials
Efficacy
Benefit
ratings
Muscle
Anti-aging
Inflammation
Growth
Hormone Support
Technical Data
Compound
specifications
Vesilute
Molecular Formula
C9H14N2O7
Molecular Weight
262.2 g/mol
Half-Life
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids via standard pathways
Bioavailability
High oral bioavailability for a dipeptide — absorbed intact by intestinal peptide transporter PepT1 (SLC15A1); ultra-short structure enables efficient cellular uptake and nuclear penetration
CAS Number
3918-84-1
Prostamax
Molecular Formula
C20H33N5O9
Molecular Weight
487.5 g/mol
Half-Life
Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through chromatin remodeling at prostate gene promoters; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to short tetrapeptide structure with proline conferring conformational stability
CAS Number
Not publicly registered
Protocols
Dosing
tiers
Vesilute
Prostamax
Applications
Best
suited for
Vesilute
Supporting bladder health and urinary function in aging individuals
Vesilute is particularly well-suited for individuals focused on supporting bladder health and urinary function in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Bioregulatory approach to benign prostatic hyperplasia (BPH) management
Vesilute is particularly well-suited for individuals focused on bioregulatory approach to benign prostatic hyperplasia (bph) management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic urogenital inflammation through epigenetic mechanisms
Vesilute is particularly well-suited for individuals focused on reducing chronic urogenital inflammation through epigenetic mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing standard urological treatments with peptide bioregulator therapy
Vesilute is particularly well-suited for individuals focused on complementing standard urological treatments with peptide bioregulator therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Prostamax
Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
Prostamax is particularly well-suited for individuals focused on age-related benign prostatic hyperplasia (bph) requiring tissue-level normalization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Prostate geroprotection — preserving prostatic epithelial function during aging
Prostamax is particularly well-suited for individuals focused on prostate geroprotection — preserving prostatic epithelial function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
Prostamax is particularly well-suited for individuals focused on chronic prostatitis support through anti-inflammatory tissue-level mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting male genitourinary health
Prostamax is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male genitourinary health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Vesilute
Common
- Mild gastrointestinal discomfort
- Increased urinary frequency initially
- Mild headache
- Minor fatigue
Uncommon
- Injection site irritation
Serious
- No documented serious adverse effects
Prostamax
Common
- Injection site reaction
- Mild fatigue
- Urinary frequency changes
- Mild headache
Uncommon
- Mild pelvic discomfort
Serious
- No documented serious adverse effects
Research Status
Safety
& evidence
Vesilute
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Vesilute (fibroin-derived peptide from Bombyx mori silk) demonstrates favorable biocompatibility from cosmetic ingredient testing with minimal allergic or irritant potential despite its animal protein origin. Limited systemic absorption occurs topically, confining effects to dermal layers with low risk of systemic toxicity. Silk-derived peptides have been used in cosmetics for >20 years without documented serious adverse events in published literature. Theoretical hypersensitivity risk exists for individuals with silk allergy, though cross-reactivity with purified peptide is low.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive urinary tract infection requiring antibiotic treatment — treat infection first
- xBladder or prostate malignancy — proliferative effects of peptide bioregulators may be contraindicated
Prostamax
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence. No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers.
Contraindications
- xKnown or suspected prostate cancer — potential modulation of prostatic gene expression requires oncological clearance
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, proline)
- xSevere urinary retention requiring surgical intervention — epigenetic therapy cannot address acute obstruction
- xConcurrent anti-androgen therapy without medical supervision — potential interaction with hormonal mechanisms
Decision Guide
Which is
right for you?
Choose Vesilute if...
- Supporting bladder health and urinary function in aging individuals
- Bioregulatory approach to benign prostatic hyperplasia (BPH) management
- Reducing chronic urogenital inflammation through epigenetic mechanisms
- Complementing standard urological treatments with peptide bioregulator therapy
Choose Prostamax if...
- Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
- Prostate geroprotection — preserving prostatic epithelial function during aging
- Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
- Comprehensive Khavinson bioregulator protocols targeting male genitourinary health